Novorex

Specialized company in the development of
new small molecule drugs targeting mostly oncology and neurology diseases
using FBDD and artificial intelligence with pharmaceutical experts.

Leadership

손우성

Woo Sung Son CEO/CKO, Founder

  • General Management, Membrane Protein Structure Analysis, Molecular Simulation and Design, Biophysical Analysis, AI-enhanced Pharmaceutical Data Science
  • Faculty at CHA University, Department of Pharmacy
  • Director of Gyeonggi-do Regional Research Center (GRRC)
  • Research Fellow at UCSD

JongSoo LimCSO

POC Confirmation in Molecular Level using Biophysical Methods, Data for Global L/O

Dong-A Socioholdings Research Institute, Molecular Pharmacology Team, Innovative Medicine Research Lab.

The Young Researcher Award from the Korean Society of Magnetic Resonance in Medicine in 2022 / 54th Annual Meeting of Korean Magnetic Resonance Society(KMRS)

HyeLin ParkCDO/CCO

Drug Development – Clinical Research and Development, Global Project Management

New Drug Development experience in full life cycle, up to Phase 3 studies and NDA – CML, Parkinson’s Disease drug, etc.

IL-YANG PHARM Co., Ltd., Head of Clinical Research Team

G2G Bio, Director/Clinical Development

IR52 Jang-Youngshil Award (CML drug part, KOITA)

Excellent Expert on Innovation and Commercialization in Pharmaceutical Industry, The 19th Korea New Drug Award, KHIDI

JuneYoung LeeCOO/CBDO

General Management, BD experiences in global companies, M&A experience, Wide network with MNC pharma’s managements

R&D experience in Research Institutes (KRICT, POSTECH, etc.)

Head/Director-level of Business Development in various CRO (IQVIA, Labcorp, ICON, etc.)

Hanho ChoiCFO/CHRO

Financial Statements Audit, K-SOX Audit, Finance Due Diligence, IFRS Conversion, Valuation, K-SOX establishment

Samil PwC, Assurance

KICPA & AICPA

TOP